Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens  

作　　者：Rui Lu Meng Zhang Zi-Han Liu Miao Hao Yan Tian Mei Li Feng-Ping Wu Wen-Jun Wang Juan-Juan Shi Xin Zhang Xiao-Li Jia Zi-Cheng Jiang Xue-Mei Li Guang-Hua Xu Ya-Ping Li Shuang-Suo Dang 

机构地区：[1]Department of Infectious Diseases,The Second Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710004,Shaanxi Province,China [2]Department of Infectious Diseases,Ankang Central Hospital,Ankang 725000,Shaanxi Province,China [3]Department of Infectious Diseases,The Affiliated Hospital of Yan’an University,Yan’an 716000,Shaanxi Province,China

出　　处：《World Journal of Gastroenterology》2024年第44期4725-4737,共13页世界胃肠病学杂志（英文）

基　　金：Supported by National Key Research and Development Program of China,No.2023YFC2308105.

摘　　要：BACKGROUND The long-term stability of hepatitis B surface antigen(HBsAg)seroclearance following peginterferon alpha(peg-IFN-α)-based therapy has not been extensively studied,leaving the full potential and limitations of this strategy unclear.AIM To assess HBsAg recurrence after seroclearance achieved by peg-IFN-αregimens.METHODS This prospective,multicenter,observational study was conducted from November 2015 to June 2021 at three Chinese hospitals:The Second Affiliated Hospital of Xi’an Jiaotong University,Ankang Central Hospital,and The Affiliated Hospital of Yan’an University.Participants who achieved HBsAg seroclearance following peg-IFN-α-based treatments were monitored every 4-12 weeks post-treatment for hepatitis B virus(HBV)markers,HBV DNA,and liver function.The primary outcome was HBV recurrence,defined as the reemergence of HBsAg,HBV DNA,or both,at least twice within 4-8 weeks of follow-up.RESULTS In total,121 patients who achieved HBsAg seroclearance were enrolled.After a median follow-up of 84.0(48.0,132.0)weeks,four subjects were lost to follow-up.HBsAg recurrence was detected in 16 patients.The cumulative HBsAg recurrence rate in the intention-to-treat population was 15.2%.Multivariate logistic regression analysis demonstrated that consolidation time<12 weeks[odds ratio(OR)=28.044,95%CI:4.525-173.791]and hepatitis B surface antibody disappearance during follow-up(OR=46.445,95%CI:2.571-838.957)were strong predictors of HBsAg recurrence.HBV DNA positivity and decompensation of liver cirrhosis and hepatocellular carcinoma were not observed.CONCLUSION HBsAg seroclearance following peg-IFN-αtreatment was durable over 84 weeks of follow-up with a cumulative recurrence rate of 15.2%.

关 键 词：Chronic hepatitis B Peginterferon alpha Hepatitis B surface antigen seroclearance Hepatitis B surface antigen recurrence Clinical cure 

分 类 号：R512.62[医药卫生—内科学]